In September, the U.S. Food and Drug Administration (FDA) announced that it has launched a pilot program aimed at streamlining the agency’s review of certain premarket tobacco product applications (PMTAs) for modern oral nicotine pouches.
The announcement notes that evidence suggests nicotine pouches can help adults switch away from more harmful tobacco products. Although nicotine pouch PMTAs will still be subject to the traditional case-by-case review, FDA says the pilot program will “increase efficiency by focusing review on the most critical elements for this product category to determine whether permitting the marketing of a product is appropriate for the protection of the public health.”
Communication between FDA and applicants appears to be a key feature of the pilot program. Real-time feedback to applicants could result in shorter review timeframes, the agency said in its announcement. This communication could allow applicants to clarify misunderstandings or provide missing information during FDA’s review process, thereby cutting down on the number and severity of issues included in a deficiency letter.
Reportedly, the pilot program could also entail FDA relaxing certain requirements for manufacturers to submit product-specific studies in their PMTAs. However, the agency has yet to publicly confirm whether the program will involve dropping product-specific study requirements in favor of more general literature regarding nicotine pouches.
Why It Matters
FDA’s announcement of the nicotine pouch pilot program is a notable commitment to more efficient PMTA review for a class of products widely considered to be low on the spectrum of risk. Viewed more broadly, this announcement indicates that FDA is supporting tobacco harm reduction and potentially allowing consumers more choices for lawful nicotine consumption.
Our team will continue to monitor the forthcoming practical impacts and implications of the program. It remains to be seen is whether the pilot program is extended to all nicotine pouch PMTAs, versus the products that were identified as being subject to the program. It also remains to be seen whether FDA relaxes requirements for product-specific studies versus (for example) evidence showing that the candidate products facilitate cessation or reduction of more harmful product use. Further, time will tell if the pilot program has any impact on certain companies’ stated approach to marketing pouch products in advance of formal marketing authorization. “The proof is in the pudding,” as they say, and more will be revealed when FDA acts on pending nicotine pouch PMTAs.